Find drug development pipeline and deal Updates information

Lead Product(s): ACT-709478

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Neurocrine Biosciences

Deal Size: $417.0 million Upfront Cash: $45.0 million

Deal Type: Licensing Agreement January 10, 2020

Details:

Under this agreement, Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsy.